S
DNTH icon

SignatureFD’s Dianthus Therapeutics DNTH Stock Holding History

SignatureFD’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4K Buy
124
+109
+727% +$6.31K ﹤0.01% 2493
2025
Q4 		$618 Buy
15
+7
+88% +$271 ﹤0.01% 3195
2025
Q3 		$315 Hold
8
– – ﹤0.01% 3243
2025
Q2 		$149 Buy
+8
New +$150 ﹤0.01% 3188
2021
Q4 		– Sell
-5
Closed -$1K – 3139
2021
Q3 		$1K Buy
+5
New +$583 ﹤0.01% 2807

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SignatureFD's DNTH Position: Q1 2026 in Review

SignatureFD increased its Dianthus Therapeutics (DNTH) stake by 727% in Q1 2026, buying an estimated $6.31K and bringing the position to 124 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2493.

SignatureFD first reported a position in DNTH in Q3 2021 and has held it in 5 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • SignatureFD held 124 shares of Dianthus Therapeutics worth $10.4K as of Q1 2026.
  • SignatureFD bought 109 Dianthus Therapeutics shares in Q1 2026, an estimated $6.31K.
  • Dianthus Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #2493 holding.
  • SignatureFD first reported a position in Dianthus Therapeutics in Q3 2021 and has held it in 5 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.